Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-centre, Open-label, Single-arm, Dose-finding Phase I/II Study to Evaluate Safety, Tolerability, Dosing Schedule, and Preliminary Efficacy of Carrier-added 4-L-[131I]Iodo-phenylalanine (131I-IPA), Administered as Single or Repetitive Injections in Patients With Recurrent Glioblastoma Multiforme (GBM), Concomitantly to 2nd Line External Radiation Therapy (XRT) - IPAX- 1

NCT03849105 is registered in ClinicalTrials.gov with Telix Pharmaceuticals (Innovations) Pty Limited as lead sponsor.

NCT NCT03849105
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03849105 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-centre, Open-label, Single-arm, Dose-finding Phase I/II Study to Evaluate Safety, Tolerability, Dosing Schedule, and Preliminary Efficacy of Carrier-added 4-L-[131I]Iodo-phenylalanine (131I-IPA), Administered as Single or Repetitive Injections in Patients With Recurrent Glioblastoma Multiforme (GBM), Concomitantly to 2nd Line External Radiation Therapy (XRT) - IPAX- 1
Lead sponsor
Telix Pharmaceuticals (Innovations) Pty Limited
Phase
Phase 1/2
Overall status
Completed
Start date
April 9, 2019
Completion date
October 31, 2022
Enrollment
10 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma multiforme